Merck KGaA Q2 Earnings Call Highlights

Key Points

• Merck KGaA reported strong Q2 growth, with organic sales up 4.1% and EBITDA pre rising 9.3% organically to €1.6 billion. Life Science and Electronics led performance, driven by Process Solutions and advanced semiconductor demand.
• The company raised its 2026 outlook for organic sales growth to 1%–3%, EBITDA pre to €5.9–€6.3 billion and EPS pre to €7.90–€8.60. Electronics guidance was upgraded notably, while Healthcare still expects an organic sales decline due to U.S. competition and Mavenclad exclusivity loss.
• Merck remains on track to acquire Bio-Techne by the end of 2026 or early 2027, expecting about €140 million in annual cost synergies by the third year after closing, though management emphasized the need to maintain cash generation and reduce debt.

Merck KGaA ETR: MRK reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre and earnings per share.

Group net sales rose 3.4% year over year to €5.434 billion. Organic sales grew 4.1%, while currency effects reduced sales by 1.1% and portfolio effects added 0.4%. EBITDA pre increased 9.4% on a reported basis to €1.6 billion, with organic growth of 9.3%. The EBITDA pre margin expanded by 1.6 percentage points to 29.4%.

“Q2 was a pretty robust quarter,” Group Chief Executive Officer Kai Beckmann said, citing growth momentum in Life Science and Electronics as well as continued contributions from rare-disease products in Healthcare.

Life Science Growth Driven by Process Solutions

Life Science organic sales increased 8% in the quarter, with Process Solutions growing 15%. Chief Financial Officer Helene von Roeder said the business continued to benefit from healthy underlying demand, stronger purchasing activity in Asia-Pacific and new customer projects, although the temporary uplift began normalizing during the quarter.

Advanced Solutions grew 4% organically as the research-spending environment improved gradually, while Discovery Solutions increased 2% despite continued market softness, including in China. Life Science EBITDA pre rose to €700 million, and the margin increased 50 basis points to 29%.

Jean-Charles Wirth, CEO of Life Science, said Process Solutions’ full-year growth is expected to land in the upper end of the company’s previously cited 8% to 12% range. Its first-half book-to-bill ratio was above one, he said.

Wirth said the company does not expect inventory destocking to affect Process Solutions in 2026, though any such effect could occur in 2027. He added that roughly 75% to 80% of orders had lead times of one to six months at the end of June, consistent with pre-pandemic order patterns.

Merck also said it remains on track to acquire Bio-Techne, subject to regulatory approvals and closing, which is expected by the end of 2026 or early 2027. The company expects the acquisition to be immediately accretive to sales growth and EBITDA pre margin after closing. It estimates annual run-rate cost synergies of about €140 million by the third year after closing and expects group EPS pre accretion in that year.

Healthcare Sales Reflect Portfolio Effects and U.S. Competition

Healthcare reported sales rose 2.4% to €2.2 billion, but organic sales declined 3.4%. Positive portfolio effects from the rare-disease portfolio added 5.4% to reported sales.

Rare-disease products Auxilium and GOMEKLI generated combined first-half sales of €207 million, in line with company guidance. Merck also recorded initial sales of pimicotinib following its private-market launch in China.

Specialty Care sales declined 6% organically, primarily due to Mavenclad’s loss of market exclusivity in the U.S. and competition for BAVENCIO. Erbitux sales increased 5% organically. Cardiometabolic sales rose 1% organically, while Fertility & Endocrinology was broadly stable.

Healthcare EBITDA pre was €747 million, representing a 34.7% margin. Von Roeder said favorable product mix and cost management partly offset higher research and development spending and launch investments for rare-disease products.

In the pipeline, Merck dosed the first patient in a phase III trial of Precem-TcT, an anti-CEACAM5 antibody-drug conjugate for third-line metastatic colorectal cancer. The FDA also granted breakthrough therapy designation to enpatoran for lupus with active cutaneous manifestations.

The FDA accepted Merck’s biologics license application for Pergoveris, but Healthcare CEO Danny Bar-Zohar said uncertainty remains over potential approval because the submission relies substantially on legacy data generated outside the U.S. Merck’s 2026 guidance does not include a potential U.S. Pergoveris launch.

Electronics Gains From Advanced Semiconductor Demand

Electronics organic sales growth accelerated to 11.7%, while reported sales totaled €871 million, reflecting the divestment of Surface Solutions. Semiconductor Solutions grew 17% organically, supported by demand for semiconductor materials used in advanced logic and memory nodes.

Ben Hein, CEO of Electronics, said AI-related applications and data-center buildouts continued to drive demand, while consumer-electronics markets remained softer. He said the company expects shortages of advanced memory chips and elevated prices to persist at least through the second half of 2027.

Delivery Systems & Services also contributed to quarterly growth following the completion of a large project, although Hein cautioned that the contribution is unlikely to recur. Optronics was broadly stable but faces increasing pressure from consumer-electronics demand in the second half.

Electronics EBITDA pre rose to €244 million and the margin reached 28%, up about 200 basis points sequentially from the underlying first-quarter margin. Management cited stronger volumes, the Surface Solutions divestment, cost management and a favorable mix from AI-driven applications.

Raised 2026 Outlook

Merck raised its 2026 guidance, now expecting group organic net sales growth of 1% to 3%, compared with its prior range of 0% to 3%. It expects reported group sales of approximately €21 billion to €21.8 billion, benefiting from less severe expected foreign-exchange headwinds.

• Group EBITDA pre is now expected at €5.9 billion to €6.3 billion, up from prior guidance of €5.7 billion to €6.1 billion.
• EPS pre is projected at €7.90 to €8.60, compared with €7.50 to €8.20 previously.
• Life Science organic sales growth is expected at 5% to 7%, including an estimated €40 million potential headwind from tariff refunds to customers.
• Healthcare organic sales are expected to decline 4% to 2%, with Merck assuming zero U.S. Mavenclad sales from August.
• Electronics organic sales growth is expected at 6% to 9%, compared with previous guidance of 3% to 7%.

Operating cash flow increased 6.7% to €605 million. Net financial debt stood at €9.2 billion at June 30, primarily reflecting the dividend payment. Von Roeder said the company’s cash-generation focus will remain important as it seeks to deleverage following the planned Bio-Techne acquisition.

About Merck KGaA (ETR:MRK)

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source